221 related articles for article (PubMed ID: 31769309)
1. Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: interim analysis from a post-marketing surveillance study.
Kaku K; Chin R; Naito Y; Iliev H; Ikeda R; Ochiai K; Yasui A
Expert Opin Drug Saf; 2020 Feb; 19(2):211-221. PubMed ID: 31769309
[No Abstract] [Full Text] [Related]
2. Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study.
Kaku K; Yamamoto K; Fukushima Y; Lliev H; Yasui A
Expert Opin Drug Saf; 2022 Oct; 21(10):1315-1328. PubMed ID: 35315729
[TBL] [Abstract][Full Text] [Related]
3. Safety and effectiveness of empagliflozin and linagliptin fixed-dose combination therapy in Japanese patients with type 2 diabetes: final results of a one-year post-marketing surveillance study.
Inagaki N; Nishimoto T; Nishiya Y; Nitta D
Expert Opin Drug Saf; 2023 Feb; 22(2):153-163. PubMed ID: 35946927
[TBL] [Abstract][Full Text] [Related]
4. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real-world clinical practice: Results of a 36-month post-marketing surveillance study (J-STEP/LT).
Utsunomiya K; Koshida R; Kakiuchi S; Senda M; Fujii S; Kurihara Y; Gunji R; Kaku K
J Diabetes Investig; 2021 Feb; 12(2):184-199. PubMed ID: 32597517
[TBL] [Abstract][Full Text] [Related]
5. Safety and effectiveness of empagliflozin in clinical practice as monotherapy or with other glucose-lowering drugs in Japanese patients with type 2 diabetes: subgroup analysis of a 3-year post-marketing surveillance study.
Kaku K; Nakayama Y; Yabuuchi J; Naito Y; Kanasaki K
Expert Opin Drug Saf; 2023; 22(9):819-832. PubMed ID: 37194266
[TBL] [Abstract][Full Text] [Related]
6. Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature.
Hernandez-Quiles C; Ramirez-Duque N; Acosta-Delgado D
Curr Diabetes Rev; 2019; 15(4):259-262. PubMed ID: 30047331
[TBL] [Abstract][Full Text] [Related]
7. Japanese study of tofogliflozin with type 2 diabetes mellitus patients in an observational study of the elderly (J-STEP/EL): A 12-week interim analysis.
Utsunomiya K; Shimmoto N; Senda M; Kurihara Y; Gunji R; Kameda H; Tamura M; Mihara H; Kaku K
J Diabetes Investig; 2016 Sep; 7(5):755-63. PubMed ID: 27181254
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trials.
Watada H; Yamauchi T; Yamamoto F; Taniguchi A; Yarush L; Heilmann C; Yasui A
Expert Opin Drug Saf; 2020 Sep; 19(9):1193-1202. PubMed ID: 32552153
[TBL] [Abstract][Full Text] [Related]
9. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24-month interim analysis of a long-term post-marketing study (J-STEP/LT).
Utsunomiya K; Kakiuchi S; Senda M; Fujii S; Kurihara Y; Gunji R; Koshida R; Kameda H; Tamura M; Kaku K
J Diabetes Investig; 2020 Jul; 11(4):906-916. PubMed ID: 32034997
[TBL] [Abstract][Full Text] [Related]
10. Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance.
Inagaki N; Nangaku M; Sakata Y; Sasaki K; Mori-Anai K; Iwasaki T; Hamada K
Adv Ther; 2022 Jan; 39(1):674-691. PubMed ID: 34853985
[TBL] [Abstract][Full Text] [Related]
11. Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes.
Kohler S; Salsali A; Hantel S; Kaspers S; Woerle HJ; Kim G; Broedl UC
Clin Ther; 2016 Jun; 38(6):1299-1313. PubMed ID: 27085585
[TBL] [Abstract][Full Text] [Related]
12. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
[TBL] [Abstract][Full Text] [Related]
13. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
Mordi NA; Mordi IR; Singh JS; McCrimmon RJ; Struthers AD; Lang CC
Circulation; 2020 Nov; 142(18):1713-1724. PubMed ID: 32865004
[TBL] [Abstract][Full Text] [Related]
14. Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post-marketing study (J-STEP/EL Study).
Utsunomiya K; Shimmoto N; Senda M; Kurihara Y; Gunji R; Fujii S; Kakiuchi S; Fujiwara H; Kameda H; Tamura M; Kaku K
J Diabetes Investig; 2017 Nov; 8(6):766-775. PubMed ID: 28107773
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus.
Mirabelli M; Chiefari E; Caroleo P; Vero R; Brunetti FS; Corigliano DM; Arcidiacono B; Foti DP; Puccio L; Brunetti A
J Diabetes Res; 2019; 2019():3971060. PubMed ID: 31781664
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of canagliflozin in elderly patients with type 2 diabetes mellitus: a 1-year post-marketing surveillance in Japan.
Goda M; Yamakura T; Sasaki K; Tajima T; Ueno M
Curr Med Res Opin; 2018 Feb; 34(2):319-327. PubMed ID: 29025285
[TBL] [Abstract][Full Text] [Related]
17. Design of a 24-week trial of empagliflozin once daily in hypertensive black/African American patients with type 2 diabetes mellitus.
Ferdinand KC; Seman L; Salsali A
Curr Med Res Opin; 2018 Feb; 34(2):361-367. PubMed ID: 29139301
[TBL] [Abstract][Full Text] [Related]
18. Safety and effectiveness of empagliflozin according to body mass index in Japanese patients with type 2 diabetes: a subgroup analysis of a 3-year post-marketing surveillance study.
Kaku K; Yamamoto K; Fukushima Y; Mizuno S; Nitta D
Expert Opin Drug Saf; 2022 Nov; 21(11):1411-1422. PubMed ID: 35379060
[TBL] [Abstract][Full Text] [Related]
19. Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study.
Nakamura I; Maegawa H; Tobe K; Uno S
Adv Ther; 2019 Apr; 36(4):923-949. PubMed ID: 30767112
[TBL] [Abstract][Full Text] [Related]
20. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world practice: Results of 12-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT).
Utsunomiya K; Senda M; Kakiuchi S; Kameda H; Tamura M; Kurihara Y; Gunji R; Fujii S; Kaku K
J Diabetes Investig; 2020 Jan; 11(1):132-141. PubMed ID: 31197929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
